Given continued failure of BACE1 inhibitor programs at symptomatic and prodromal stages of Alzheimer’s disease (AD), clinical trials need to target the earlier preclinical stage. However, trial design is complex in this population with negative diagnosis of classical hippocampal amnesia on standard memory tests. Besides recent advances in brain imaging, electroencephalogram, and fluid-based biomarkers, new cognitive markers should be established for earlier diagnosis that can optimize recruitment to BACE1 inhibitor trials in presymptomatic AD. Notably, accelerated long-term forgetting (ALF) is emerging as a sensitive cognitive measure that can discriminate between asymptomatic individuals with high risks for developing AD and healthy controls. ALF is a form of declarative memory impairment characterized by increased forgetting rates over longer delays (days to months) despite normal storage within the standard delays of testing (20–60 min). Therefore, ALF may represent a harbinger of preclinical dementia and the impairment of systems memory consolidation, during which memory traces temporarily stored in the hippocampus become gradually integrated into cortical networks. This review provides an overview of the utility of ALF in a rational design of next-generation BACE1 inhibitor trials in preclinical AD. I explore potential mechanisms underlying ALF and relevant early-stage biomarkers useful for BACE1 inhibitor evaluation, including synaptic protein alterations, astrocytic dysregulation and neuron hyperactivity in the hippocampal-cortical network. Furthermore, given the physiological role of the isoform BACE2 as an AD-suppressor gene, I also discuss the possible association between the poor selectivity of BACE1 inhibitors and their side effects (e.g., cognitive worsening) in prior clinical trials.
YadollahikhalesG, RojasJC (2023) Anti-amyloid immunotherapies for Alzheimer’s disease: A 2023 clinical update. Neurotherapeutics20, 914–931.
3.
GandyS (2023) News & views: Anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023. Mol Neurodegener18, 66.
4.
ImbimboBP, WatlingM (2019) Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs28, 967–975.
5.
McDadeE, VoytyukI, AisenP, BatemanRJ, CarrilloMC, De StrooperB, HaassC, ReimanEM, SperlingR, TariotPN, YanR, MastersCL, VassarR, LichtenthalerSF (2021) The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol17, 703–714.
6.
BazzariFH, BazzariAH (2022) BACE1 inhibitors for Alzheimer’s disease: The past, present and any future?Molecules27, 8823.
LuoJE, LiYM (2022) Turning the tide on Alzheimer’s disease: Modulation of γ-secretase. Cell Biosci12, 2.
9.
OhnoM (2016) Alzheimer’s therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. Brain Res Bull126, 183–198.
10.
NixonRA (2017) Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: Inseparable partners in a multifactorial disease. FASEB J31, 2729–2743.
11.
KwartD, GreggA, ScheckelC, MurphyE, PaquetD, DuffieldM, FakJ, OlsenO, DarnellR, Tessier-LavigneM (2019) A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, not Aβ
. Neuron104, 256–270.
12.
BourgeoisA, LauritzenI, LorivelT, BauerC, CheclerF, Pardossi-PiquardR (2018) Intraneuronal accumulation of C99 contributes to synaptic alterations, apathy-like behavior, and spatial learning deficits in 3×TgAD and 2×TgAD mice. Neurobiol Aging71, 21–31.
13.
PulinaMV, HopkinsM, HaroutunianV, GreengardP, BustosV (2020) C99 selectively accumulates in vulnerable neurons in Alzheimer’s disease. Alzheimers Dement16, 273–282.
O’ConnorA, WestonPSJ, PavisicIM, RyanNS, CollinsJD, LuK, CrutchSJ, AlexanderDC, FoxNC, OxtobyNP (2020) Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer’s disease: A retrospective cohort analysis. Alzheimers Res Ther12, 126.
30.
YangJ, KongC, JiaL, LiT, QuanM, LiY, LyuD, LiF, JinH, LiY, WangQ, JiaJ (2021) Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer’s disease. Alzheimers Res Ther13, 107.
31.
ManesF, SerranoC, CalcagnoML, CardozoJ, HodgesJ (2008) Accelerated forgetting in subjects with memory complaints: A new form of mild cognitive impairment?J Neurol255, 1067–1070.
32.
Tort-MerinoA, ValechN, LaineM, OlivesJ, LeónM, Ecay-TorresM, EstangaA, Martínez-LageP, ForteaJ, MolinuevoJL, Sánchez-ValleR, Rodriguez-FornellsA, RamiL (2021) Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity. Int J Geriatr Psychiatry36, 1037–1049.
33.
RamiL, LeónM, ValechN, Coll-PadrósN, BoschB, OlivesJ, SalineroA, Pérez-MillanA, MolinuevoJL, Sánchez-ValleR, Tort-MerinoA (2023) Design and validation of the 1-week memory battery for assessing episodic memory and accelerated long-term forgetting in cognitively unimpaired subjects. Neuropsychology37, 683–697.
34.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChételatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM, Subjective Cognitive Decline Initiative (SCD-I) Working Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
35.
MameniškienėR, PuteikisK, JasionisA, JatužisD (2020) A review of accelerated long-term forgetting in epilepsy. Brain Sci10, 945.
36.
RodiniM, De SimoneMS, CaltagironeC, CarlesimoGA (2022) Accelerated long-term forgetting in neurodegenerative disorders: A systematic review of the literature. Neurosci Biobehav Rev141, 104815.
37.
OhnoM (2023) Accelerated long-term forgetting: A sensitive paradigm for detecting subtle cognitive impairment and evaluating BACE1 inhibitor efficacy in preclinical Alzheimer’s disease. Front Dement2, 1161875.
38.
García-MartínezM, Sánchez-JuanP, ButlerCR (2023) A review of accelerated long-term forgetting in Alzheimer’s disease: Current situation and prospects. Neuropsychology37, 673–682.
39.
OhnoM (2021) Accelerated long-term forgetting is a BACE1 inhibitor-reversible incipient cognitive phenotype in Alzheimer’s disease model mice. Neuropsychopharmacol Rep41, 255–259.
40.
OakleyH, ColeSL, LoganS, MausE, ShaoP, CraftJ, Guillozet-BongaartsA, OhnoM, DisterhoftJ, Van EldikL, BerryR, VassarR (2006) Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci26, 10129–10140.
41.
OhnoM, ChangL, TsengW, OakleyH, CitronM, KleinWL, VassarR, DisterhoftJF (2006) Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1. Eur J Neurosci23, 251–260.
42.
Botella LucenaP, VanherleS, LodderC, Gutiérrez de RavéM, StancuIC, LambrichtsI, VangheluweR, BruffaertsR, DewachterI (2022) Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: Opening new avenues for prevention. Acta Neuropathol144, 489–508.
IaccarinoL, BurnhamSC, Dell’AgnelloG, DowsettSA, EpelbaumS (2023) Diagnostic biomarkers of amyloid and tau pathology in Alzheimer’s disease: An overview of tests for clinical practice in the United States and Europe. J Prev Alzheimers Dis10, 426–442.
45.
SyvänenS, MeierSR, RoshanbinS, XiongM, FaresjöR, GustavssonT, BonviciniG, SchleinE, AguilarX, JulkuU, ErikssonJ, SehlinD (2022) PET imaging in preclinical anti-Aβ drug development. Pharm Res39, 1481–1496.
46.
FranklandPW, BontempiB (2005) The organization of recent and remote memories. Nat Rev Neurosci6, 119–130.
47.
TonegawaS, MorrisseyMD, KitamuraT (2018) The role of engram cells in the systems consolidation of memory. Nat Rev Neurosci19, 485–498.
48.
KlinzingJG, NiethardN, BornJ (2019) Mechanisms of systems memory consolidation during sleep. Nat Neurosci22, 1598–1610.
49.
PalmqvistS, SchöllM, StrandbergO, MattssonN, StomrudE, ZetterbergH, BlennowK, LandauS, JagustW, HanssonO (2017) Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun8, 1214.
50.
ManderBA (2020) Local sleep and Alzheimer’s disease pathophysiology. Front Neurosci14, 525970.
51.
ChenC, MaX, WeiJ, ShakirN, ZhangJK, ZhangL, NehmeA, CuiY, FergusonD, BaiF, QiuS (2022) Early impairment of cortical circuit plasticity and connectivity in the 5XFAD Alzheimer’s disease mouse model. Transl Psychiatry12, 371.
52.
YuanQ, LiangX, XueC, QiW, ChenS, SongY, WuH, ZhangX, XiaoC, ChenJ (2022) Altered anterior cingulate cortex subregional connectivity associated with cognitions for distinguishing the spectrum of pre-clinical Alzheimer’s disease. Front Aging Neurosci14, 1035746.
53.
Ben-AmiL, Ravona-SpringerR, TsarfatyG, RaizmanR, ShumacherA, Sharvit-GinonI, GreenbaumL, BendlinBB, OkunE, HeymannA, Schnaider BeeriM, LivnyA (2023) Neural correlates of subjective cognitive decline in adults at high risk for Alzheimer’s disease. Front Aging Neurosci15, 1067196.
54.
ChételatG, VillemagneVL, BourgeatP, PikeKE, JonesG, AmesD, EllisKA, SzoekeC, MartinsRN, O’KeefeGJ, SalvadoO, MastersCL, RoweCC, Australian Imaging Biomarkers and Lifestyle Research Group (2010) Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann Neurol67, 317–324.
55.
PezzoliS, GiorgioJ, MartersteckA, DobynsL, HarrisonTM, JagustWJ (2024) Successful cognitive aging is associated with thicker anterior cingulate cortex and lower tau deposition compared to typical aging. Alzheimers Dement20, 341–355.
56.
MayesAR, HunkinNM, IsaacC, MuhlertN (2019) Are there distinct forms of accelerated forgetting and, if so, why?Cortex110, 115–126.
57.
BuscheMA, KonnerthA (2015) Neuronal hyperactivity - A key defect in Alzheimer’s disease?Bioessays37, 624–632.
58.
PalopJJ, MuckeL (2010) Amyloid-β-induced neuronal dysfunction in Alzheimer’s disease: From synapses toward neural networks. Nat Neurosci13, 812–818.
59.
PalopJJ, MuckeL (2016) Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci17, 777–792.
60.
BuscheMA, ChenX, HenningHA, ReichwaldJ, StaufenbielM, SakmannB, KonnerthA (2012) Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A109, 8740–8745.
61.
ZottB, SimonMM, HongW, UngerF, Chen-EngererHJ, FroschMP, SakmannB, WalshDM, KonnerthA (2019) A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science365, 559–565.
62.
KeskinAD, KekušM, AdelsbergerH, NeumannU, ShimshekDR, SongB, ZottB, PengT, FörstlH, StaufenbielM, NelkenI, SakmannB, KonnerthA, BuscheMA (2017) BACE inhibition-dependent repair of Alzheimer’s pathophysiology. Proc Natl Acad Sci U S A114, 8631–8636.
63.
KucikovaL, GoerdtenJ, DounaviME, MakE, SuL, WaldmanAD, DansoS, Muniz-TerreraG, RitchieCW (2021) Resting-state brain connectivity in healthy young and middle-aged adults at risk of progressive Alzheimer’s disease. Neurosci Biobehav Rev129, 142–153.
64.
Latif-HernandezA, ShahD, CraessaertsK, SaidoT, SaitoT, De StrooperB, Van der LindenA, D’HoogeR (2019) Subtle behavioral changes and increased prefrontal-hippocampal network synchronicity in APPNL-G-F mice before prominent plaque deposition. Behav Brain Res364, 431–441.
65.
ShahD, PraetJ, Latif HernandezA, HöflingC, AnckaertsC, BardF, MorawskiM, DetrezJR, PrinsenE, VillaA, De VosW, MaggiA, D’HoogeR, BalschunD, RossnerS, VerhoyeM, Van der LindenA (2016) Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition. Alzheimers Dement12, 964–976.
66.
ShahD, Latif-HernandezA, De StrooperB, SaitoT, SaidoT, VerhoyeM, D’HoogeR, Van der LindenA (2018) Spatial reversal learning defect coincides with hypersynchronous telencephalic BOLD functional connectivity in APPNL-F/NL-F knock-in mice. Sci Rep8, 6264.
67.
SzaboAB, CretinB, GérardF, CurotJ, BarbeauEJ, ParienteJ, DahanL, ValtonL (2022) Sleep: The tip of the iceberg in the bidirectional link between Alzheimer’s disease and epilepsy. Front Neurol13, 836292.
68.
VosselKA, RanasingheKG, BeagleAJ, MizuiriD, HonmaSM, DowlingAF, DarwishSM, Van BerloV, BarnesDE, MantleM, KarydasAM, CoppolaG, RobersonED, MillerBL, GarciaPA, KirschHE, MuckeL, NagarajanSS (2016) Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease. Ann Neurol80, 858–870.
69.
Hautecloque-RayszG, SellalF, BousigesO, PhillipiN, BlancF, CretinB (2023) . Epileptic prodromal Alzheimer’s disease treated with antiseizure medications: Medium-term outcome of seizures and cognition. J Alzheimers Dis94, 1057–1074.
70.
YaoAY, HalloranPJ, GeY, SinghN, ZhouJ, GalskeJ, HeW, YanR, HuX (2023) Bace1 deletion in the adult reverses epileptiform activity and sleep-wake disturbances in AD mice. J Neurosci43, 6197–6211.
71.
BlakeRV, WroeSJ, BreenEK, McCarthyRA (2000) Accelerated forgetting in patients with epilepsy: Evidence for an impairment in memory consolidation. Brain123, 472–483.
72.
HolleyAJ, HodgesSL, NolanSO, BinderM, OkohJT, AckermanK, TomacLA, LugoJN (2018) A single seizure selectively impairs hippocampal-dependent memory and is associated with alterations in PI3K/Akt/mTOR and FMRP signaling. Epilepsia Open3, 511–523.
VosselKA, BeagleAJ, RabinoviciGD, ShuH, LeeSE, NaasanG, HegdeM, CornesSB, HenryML, NelsonAB, SeeleyWW, GeschwindMD, Gorno-TempiniML, ShihT, KirschHE, GarciaPA, MillerBL, MuckeL (2013) Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol70, 1158–1166.
75.
VosselKA, TartagliaMC, NygaardHB, ZemanAZ, MillerBL (2017) Epileptic activity in Alzheimer’s disease: Causes and clinical relevance. Lancet Neurol16, 311–322.
76.
NousA, SeynaeveL, FeysO, WensV, De TiègeX, Van MierloP, BaroumandA, NieboerK, AllemeerschGJ, MangelschotsS, MichielsV, van der ZeeJ, Van BroeckhovenC, RibbensA, HoubrechtsR, De WitteS, WittensMMJ, BjerkeM, VanlersbergheC, CeyssensS, NagelsG, SmoldersI, EngelborghsS (2024) Subclinical epileptiform activity in the Alzheimer continuum: Association with disease, cognition and detection method. Alzheimers Res Ther16, 19.
77.
HickmanLB, SternJM, SilvermanDHS, SalamonN, VosselK (2023) Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology. Front Neurol14, 1241638.
78.
BoscoF, GuarnieriL, RaniaV, PalmaE, CitraroR, CorasanitiMT, LeoA, De SarroG (2023) Antiseizure medications in Alzheimer’s disease from preclinical to clinical evidence. Int J Mol Sci24, 12639.
StaresinaBP, BergmannTO, BonnefondM, van der MeijR, JensenO, DeukerL, ElgerCE, AxmacherN, FellJ (2015) Hierarchical nesting of slow oscillations, spindles and ripples in the human hippocampus during sleep. Nat Neurosci18, 1679–1686.
81.
KhodagholyD, GelinasJN, BuzsákiG (2017) Learning-enhanced coupling between ripple oscillations in association cortices and hippocampus. Science358, 369–372.
82.
KatsukiF, GerashchenkoD, BrownRE (2022) Alterations of sleep oscillations in Alzheimer’s disease: A potential role for GABAergic neurons in the cortex, hippocampus, and thalamus. Brain Res Bull187, 181–198.
83.
ZhurakovskayaE, IshchenkoI, GurevicieneI, AlievR, GröhnO, TanilaH (2019) Impaired hippocampal-cortical coupling but preserved local synchrony during sleep in APP/PS1 mice modeling Alzheimer’s disease. Sci Rep9, 5380.
84.
JuYE, LuceyBP, HoltzmanDM (2014) Sleep and Alzheimer disease pathology - A bidirectional relationship. Nat Rev Neurol10, 115–119.
85.
MinakawaEN, WadaK, NagaiY (2019) Sleep disturbance as a potential modifiable risk factor for Alzheimer’s disease. Int J Mol Sci20, 803.
86.
WinerJR, ManderBA, KumarS, ReedM, BakerSL, JagustWJ, WalkerMP (2020) Sleep disturbance forecasts β-amyloid accumulation across subsequent years. Curr Biol30, 4291–4298.e4293.
87.
ChylinskiD, Van EgrooM, NarbutasJ, MutoV, BahriMA, BerthomierC, SalmonE, BastinC, PhillipsC, ColletteF, MaquetP, CarrierJ, LinaJM, VandewalleG (2022) Timely coupling of sleep spindles and slow waves linked to early amyloid-β burden and predicts memory decline. eLife11, e78191.
88.
BezzinaC, VerretL, JuanC, RemaudJ, HalleyH, RamponC, DahanL (2015) Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer’s disease. PLoS One10, e0119910.
89.
KamK, DuffyáM, MorettoJ, LaFrancoisJJ, ScharfmanHE (2016) Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-amyloid neuropathology. Sci Rep6, 20119.
90.
KazimSF, ChuangSC, ZhaoW, WongRK, BianchiR, IqbalK (2017) Early-onset network hyperexcitability in presymptomatic Alzheimer’s disease transgenic mice is suppressed by passive immunization with anti-human APP/Aβ antibody and by mGluR5 blockade. Front Aging Neurosci9, 71.
91.
XuW, FitzgeraldS, NixonRA, LevyE, WilsonDA (2015) Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of AβPP metabolites in the Tg2576 mouse model of Alzheimer’s disease. Exp Neurol264, 82–91.
DurkeeCA, AraqueA (2019) Diversity and specificity of astrocyte-neuron communication. Neuroscience396, 73–78.
101.
OliveiraJF, AraqueA (2022) Astrocyte regulation of neural circuit activity and network states. Glia70, 1455–1466.
102.
KolA, AdamskyA, GroysmanM, KreiselT, LondonM, GoshenI (2020) Astrocytes contribute to remote memory formation by modulating hippocampal-cortical communication during learning. Nat Neurosci23, 1229–1239.
103.
KitamuraT, OgawaSK, RoyDS, OkuyamaT, MorrisseyMD, SmithLM, RedondoRL, TonegawaS (2017) Engrams and circuits crucial for systems consolidation of a memory. Science356, 73–78.
LeeHS, GhettiA, Pinto-DuarteA, WangX, DziewczapolskiG, GalimiF, Huitron-ResendizS, Piña-CrespoJC, RobertsAJ, VermaIM, SejnowskiTJ, HeinemannSF (2014) Astrocytes contribute to gamma oscillations and recognition memory. Proc Natl Acad Sci U S A111, E3343–3352.
106.
Pinto-DuarteA, RobertsAJ, OuyangK, SejnowskiTJ (2019) Impairments in remote memory caused by the lack of Type 2 IP3 receptors. Glia67, 1976–1989.
107.
HulshofLA, van NuijsD, HolEM, MiddeldorpJ (2022) The role of astrocytes in synapse loss in Alzheimer’s disease: A systematic review. Front Cell Neurosci16, 899251.
108.
FurmanJL, SamaDM, GantJC, BeckettTL, MurphyMP, BachstetterAD, Van EldikLJ, NorrisCM (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer’s disease. J Neurosci32, 16129–16140.
KuchibhotlaKV, LattaruloCR, HymanBT, BacskaiBJ (2009) Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science323, 1211–1215.
113.
LinesJ, BaraibarAM, FangC, MartinED, AguilarJ, LeeMK, AraqueA, KofujiP (2022) Astrocyte-neuronal network interplay is disrupted in Alzheimer’s disease mice. Glia70, 368–378.
114.
DelekateA, FüchtemeierM, SchumacherT, UlbrichC, FoddisM, PetzoldGC (2014) Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer’s disease mouse model. Nat Commun5, 5422.
115.
BundyJL, ViedC, BadgerC, NowakowskiRS (2019) Sex-biased hippocampal pathology in the 5XFAD mouse model of Alzheimer’s disease: A multi-omic analysis. J Comp Neurol527, 462–475.
116.
HongI, KangT, YooY, ParkR, LeeJ, LeeS, KimJ, SongB, KimSY, MoonM, YunKN, KimJY, Mook-JungI, ParkYM, ChoiS (2013) Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer’s disease pathology. J Alzheimers Dis36, 321–334.
117.
DavisRL, ZhongY (2017) The biology of forgetting - A perspective. Neuron95, 490–503.
118.
RyanTJ, FranklandPW (2022) Forgetting as a form of adaptive engram cell plasticity. Nat Rev Neurosci23, 173–186.
LiuSJ, GasperiniR, FoaL, SmallDH (2010) Amyloid-β decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2. J Alzheimers Dis21, 655–666.
127.
KimS, SatoY, MohanPS, PeterhoffC, PensalfiniA, RigogliosoA, JiangY, NixonRA (2016) Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer’s disease. Mol Psychiatry21, 707–716.
PensalfiniA, KimS, SubbannaS, BleiwasC, GoulbourneCN, StavridesPH, JiangY, LeeJH, DarjiS, PawlikM, HuoC, PeddyJ, BergMJ, SmileyJF, BasavarajappaBS, NixonRA (2020) Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer’s disease. Cell Rep33, 108420.
130.
DeviL, TangJ, OhnoM (2015) Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer’s transgenic mice lessen during disease progression. Curr Alzheimer Res12, 13–21.
131.
PowersBE, SantiagoNA, StruppBJ (2018) Rapid forgetting of social learning in the Ts65Dn mouse model of Down syndrome: New evidence for hippocampal dysfunction. Behav Neurosci132, 51–56.
132.
JiangY, RigogliosoA, PeterhoffCM, PawlikM, SatoY, BleiwasC, StavridesP, SmileyJF, GinsbergSD, MathewsPM, LevyE, NixonRA (2016) Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: Role of APP-CTF. Neurobiol Aging39, 90–98.
RochinL, HurbainI, SerneelsL, FortC, WattB, LeblancP, MarksMS, De StrooperB, RaposoG, van NielG (2013) BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A110, 10658–10663.
135.
OhnoM, SametskyEA, YounkinLH, OakleyH, YounkinSG, CitronM, VassarR, DisterhoftJF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron41, 27–33.
136.
LairdFM, CaiH, SavonenkoAV, FarahMH, HeK, MelnikovaT, WenH, ChiangHC, XuG, KoliatsosVE, BorcheltDR, PriceDL, LeeHK, WongPC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci25, 11693–11709.
PratschK, UnemuraC, ItoM, LichtenthalerSF, HoriguchiN, HermsJ (2023) New highly selective BACE1 inhibitors and their effects on dendritic spine density in vivo. Int J Mol Sci24, 12283.
142.
Ou-YangMH, KurzJE, NomuraT, PopovicJ, RajapakshaTW, DongH, ContractorA, ChetkovichDM, TourtellotteWG, VassarR (2018) Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice.eaao. Sci Transl Med10, 5620.
143.
VassarR (2019) Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus: Implications for BACE1 inhibitor clinical trials. J Prev Alzheimers Dis6, 78–84.
144.
BennettBD, Babu-KhanS, LoeloffR, LouisJC, CurranE, CitronM, VassarR (2000) Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem275, 20647–20651.
145.
VoytyukI, MuellerSA, HerberJ, SnellinxA, MoecharsD, van LooG, LichtenthalerSF, De StrooperB (2018) BACE2 distribution in major brain cell types and identification of novel substrates. Life Sci Alliance1, e201800026.
146.
HollerCJ, WebbRL, LauxAL, BeckettTL, NiedowiczDM, AhmedRR, LiuY, SimmonsCR, DowlingAL, SpinelliA, KhurgelM, EstusS, HeadE, HershLB, MurphyMP (2012) BACE2 expression increases in human neurodegenerative disease. Am J Pathol180, 337–350.
LuoJ, ZouH, GuoY, HuangK, NganES, LiP (2022) BACE2 variant identified from HSCR patient causes AD-like phenotypes in hPSC-derived brain organoids. Cell Death Discov8, 47.
149.
YeapYJ, KandiahN, NizeticD, LimKL (2023) BACE2: A promising neuroprotective candidate for Alzheimer’s disease. J Alzheimers Dis94, S159–S171.
150.
FarzanM, SchnitzlerCE, VasilievaN, LeungD, ChoeH (2000) BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc Natl Acad Sci U S A97, 9712–9717.
151.
YanR, MunznerJB, ShuckME, BienkowskiMJ (2001) BACE2 functions as an alternative α-secretase in cells. J Biol Chem276, 34019–34027.
152.
SunX, HeG, SongW (2006) BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer’s disease in Down syndrome. FASEB J20, 1369–1376.
153.
FujimotoK, YoshidaS, TadanoG, AsadaN, FuchinoK, SuzukiS, MatsuokaE, YamamotoT, YamamotoS, AndoS, KanegawaN, TonomuraY, ItoH, MoecharsD, RomboutsFJR, GijsenHJM, KusakabeKI (2021) Structure-based approaches to improving selectivity through utilizing explicit water molecules: Discovery of selective β-secretase (BACE1) inhibitors over BACE2. J Med Chem64, 3075–3085.
154.
RomboutsF, KusakabeKI, HsiaoCC, GijsenHJM (2021) Small-molecule BACE1 inhibitors: A patent literature review (2011 to 2020). Expert Opin Ther Pat31, 25–52.
155.
UenoT, MatsuokaE, AsadaN, YamamotoS, KanegawaN, ItoM, ItoH, MoecharsD, RomboutsFJR, GijsenHJM, KusakabeKI (2021) Discovery of extremely selective fused pyridine-derived β-site amyloid precursor protein-cleaving enzyme (BACE1) inhibitors with high in vivo efficacy through 10s loop interactions. J Med Chem64, 14165–14174.
